ADC Therapeutics Halts Enrollment of Zynlonta Trial After Seven Patient Deaths

ADC Therapeutics announced on Tuesday that it has ceased enrollment of new patients in a Phase II of Zynlonta along with rituximab for patients with previously untreated diffuse large B cell lymphoma (DLBCL), a type of blood cancer. The reason: seven patient deaths due to extreme respiratory events.